Shares of Chimerix Inc. (NASDAQ:CMRX) climbed steadily between March 6 and March 12, even as the company was in the midst of a public relations crisis related to compassionate access to its lead compound, the antiviral brincidofovir. Following the departure of President and CEO Ken Moch on April 9, the shares traded down $1.79 to close the week at $19.85. Source: BCIQ: BioCentury Online Intelligence

A. 4/11/13 - Raises $117.9M in IPO. The stock closes at $18.79, up 34% from its IPO price of $14

B. 9/9/13 - Starts Phase III SUPPRESS trial of brincidofovir (CMX001) to prevent cytomegalovirus (CMV) in hematopoietic cell transplant (HCT) recipients

C. 10/8/13 - 180-day lockup period expires

D. 3/7/14 - Family launches social media campaign via Facebook and Twitter to persuade Chimerix to give Josh Hardy access to brincidofovir

E. 3/11/14 - Chimerix and FDA agree on an open-label pilot trial to provide access to brincidofovir to treat adenovirus infections in immunocompromised patients. Josh Hardy is the first patient in the trial

F. 3/19/14 - Josh Hardy's mother, Aimee Hardy, tells BioCentury the boy has experienced a dramatic reduction in viral load since receiving brincidofovir

G. 4/9/14 - Chimerix announces CMO M. Michelle Berrey will succeed Moch as president and CEO "following his resignation from that role to pursue other interests"